Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
1.375
+0.035 (2.61%)
At close: Sep 15, 2025, 4:00 PM EDT
1.380
+0.005 (0.36%)
After-hours: Sep 15, 2025, 4:10 PM EDT
Compugen Revenue
Compugen had revenue of $1.26M in the quarter ending June 30, 2025, a decrease of -81.24%. This brings the company's revenue in the last twelve months to $22.14M, down -48.16% year-over-year. In the year 2024, Compugen had annual revenue of $27.86M, down -16.72%.
Revenue (ttm)
$22.14M
Revenue Growth
-48.16%
P/S Ratio
5.52
Revenue / Employee
$299,243
Employees
74
Market Cap
128.61M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
Dec 31, 2020 | 2.00M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CGEN News
- 7 days ago - Compugen to Present Research at the Single Cell Genomics 2025 Conference - PRNewsWire
- 18 days ago - Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 5 weeks ago - Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients - Seeking Alpha
- 5 weeks ago - Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Compugen Reports Second Quarter 2025 Results - PRNewsWire
- 7 weeks ago - Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 - PRNewsWire
- 7 weeks ago - Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 - PRNewsWire
- 2 months ago - Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer - PRNewsWire